Pain-and-seizure-calming brain peptide (Galanin-29 [isoD18])
A lab-made modified form of galanin, a natural nerve-calming peptide, studied for its ability to reduce nerve pain and seizure activity in the brain and spinal cord. Research tool, not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Galanin-29 [isoD18] is a chemically modified form of galanin, a 29-residue neuropeptide found naturally in the nervous systems of most mammals (humans carry a slightly longer 30-residue version). The "[isoD18]" notation marks a specific structural change: the aspartate at position 18 has undergone spontaneous rearrangement to isoaspartate — a β-aspartyl linkage in which the peptide backbone shifts one carbon, subtly altering the peptide's geometry at that residue. Norberg and colleagues (2004) first isolated and characterized exactly this class of β-aspartyl-shifted galanin variants from porcine upper intestine using tandem mass spectrometry. This card represents a synthesized form of that naturally occurring variant, anchored to the rat/porcine 29-residue backbone and targeting galanin receptor type 1 (GALR1).
History
Galanin itself was isolated from porcine intestinal extracts by Viktor Mutt's group at the Karolinska Institute, with its structure published in 1983 in FEBS Letters — the name a contraction of its N-terminal glycine and C-terminal alanine. The cDNA was cloned from rat anterior pituitary in 1987, and three receptor subtypes (GALR1, GALR2, GALR3) were identified and cloned between 1993 and 1998 (Wang and colleagues 1997; Smith and colleagues 1998; Bloomquist and colleagues 1998). The existence of naturally occurring post-translationally modified galanin variants — including β-aspartyl-shifted (isoD) forms — was established by Norberg and colleagues (2004), who isolated five such variants from porcine upper intestine. More recently, Okyem and colleagues (2025, Communications Chemistry) demonstrated that roughly 20% of mature galanin in rat hypothalamus carries the L-isoaspartate modification, that aspartate spontaneously isomerizes to isoaspartate under mildly acidic conditions within 48 hours in vitro, and that the isoAsp form significantly promotes fibril formation compared to unmodified galanin — establishing the isoD variant as a biologically meaningful species, not merely a chemical curiosity.
What it does
Galanin acts broadly as an inhibitory neuromodulator. In the brain, it suppresses neuronal firing in the hippocampus, hypothalamus, and amygdala; in the spinal cord, it modulates pain signals arriving from the periphery. GALR1, the primary target of this peptide, is the receptor subtype most responsible for galanin's inhibitory and anticonvulsant effects: mice lacking the GALR1 gene develop spontaneous seizures, and selective GALR1 activation in the spinal cord suppresses mechanical allodynia in nerve-injured animals (Webling and colleagues 2012; Liu and colleagues 2001). The isoD18 modification does not abolish receptor binding — the N-terminal 16 residues, conserved in this variant, carry the main binding pharmacophore — but the backbone perturbation at position 18 in the C-terminal half alters the peptide's conformational and aggregation properties, as documented by Norberg and colleagues (2004) and Okyem and colleagues (2025).
Evidence
- Human: No clinical trials of galanin-29 [isoD18] specifically. The parent peptide galanin has been the subject of preclinical drug-discovery programs targeting GALR1 for epilepsy and neuropathic pain, with no approved therapeutic to date (Freimann and colleagues 2015).
- Animal: The galanin GALR1 axis has been extensively studied in rodent models. Intrathecal galanin suppresses allodynia in nerve-injured rats through GALR1 (Webling and colleagues 2012). GalR1-knockout mice exhibit spontaneous epilepsy, underscoring the receptor's role in seizure suppression.
- In vitro: Norberg and colleagues (2004) confirmed the β-aspartyl structure of isoD-shifted galanin variants using radioimmunoassay, chromatographic separation, and tandem mass spectrometry. Okyem and colleagues (2025) demonstrated that isoAsp-containing galanin significantly promotes fibril formation relative to unmodified galanin.
Known effects
- Neuronal inhibition (hippocampus, amygdala, spinal cord) — Established for parent galanin via GALR1; preclinical
- Anticonvulsant activity — Mediated by GALR1; extensively documented in rodent seizure models; preclinical
- Suppression of neuropathic pain (allodynia) — GALR1-dependent; shown by intrathecal administration in nerve-injured rats; preclinical
- Enhanced fibril formation — Specific to isoAsp-containing galanin; demonstrated in vitro (Okyem and colleagues 2025)
- Spontaneous isoD modification — Occurs in vivo; ~20% of galanin in rat hypothalamus carries this modification (Okyem and colleagues 2025)
Safety signals
No safety data specific to galanin-29 [isoD18] are available in the published literature. The parent peptide galanin has a well-characterized inhibitory profile in the central nervous system, and its broad inhibitory effects on appetite, memory encoding, and neuroendocrine secretion (reviewed by Webling and colleagues 2012) represent areas of pharmacological concern for any GALR1-active analog. The enhanced fibril-forming propensity of the isoD variant, relative to unmodified galanin, is a potential aggregation liability noted by Okyem and colleagues (2025).
Mechanism
GALR1 is a class A GPCR that couples selectively to the inhibitory Gαi/αo pathway. Activation inhibits adenylate cyclase, lowers intracellular cAMP, and opens inwardly rectifying potassium (GIRK) channels — collectively hyperpolarizing the neuron and suppressing firing (Webling and colleagues 2012). The receptor is expressed throughout the central and peripheral nervous system, with particularly high density in hippocampus, hypothalamus, amygdala, brainstem, spinal dorsal horn, and dorsal root ganglia. The N-terminal region of galanin (residues 1–16) is the primary pharmacophore for all three receptor subtypes; truncation beyond two N-terminal residues abolishes receptor affinity (Webling and colleagues 2012; Jiang and Zheng 2022). The [isoD18] modification falls in the C-terminal half of the peptide, which contributes less to receptor binding than to proteolytic stability — the C-terminal segment is thought to act as a shield against exopeptidases (Webling and colleagues 2012). The isoaspartate linkage introduces a one-carbon backbone extension at residue 18, altering local conformation and charge distribution without disrupting the N-terminal pharmacophore.
Regulatory status
- US: Not approved. Research use only. No IND or clinical trial registration identified for galanin-29 [isoD18].
- EU: Not approved. Research use only.
- WADA: Not listed on the current Prohibited List as a named substance; would fall under S0 (non-approved substances) if administered to competitive athletes.
Related peptides
Galanin-29 [isoD18] is a post-translationally modified form of native rat/porcine galanin. Other members of the broader galanin family include galanin-like peptide (GALP) and alarin (a splice variant of GALP); these share the conserved N-terminal pharmacophore but differ in receptor selectivity. Spexin, a more distantly related peptide, selectively activates GALR2 and GALR3 but not GALR1 due to structural clashes with GALR1's binding pocket.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could the isoD18 modification make this galanin stay bound to its target receptor longer than the unmodified version?
If confirmed, this natural modification could help explain longer-lasting pain relief or seizure suppression. It would also suggest a simple chemical trick for making other brain-targeting peptides last longer without larger doses.
Is galanin-29 [isoD18] harder for the body to degrade than normal galanin?
If true, this natural variant could stay active longer in the body, meaning lower doses could achieve the same effect. That matters for anyone developing galanin-based treatments for epilepsy or chronic pain, where sustained action is essential.
Does the isoD18 modification affect how strongly galanin binds GALR1, or only how well it activates it after binding?
Telling binding apart from activation could allow chemists to design galanin variants that bind without fully activating the receptor, a strategy used to create safer drugs. This matters for developing treatments where partial activation of GALR1 is the desired goal.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8799862265586853 | boltz-2 |
| ranking score | 0.7867307066917419 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10564,
sequence = {GWTLNSAGYLLGPHAIDNHRSFNDKHGLA},
target = {galr1},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}